Do‐Youn Oh - Publications, H-index & Citations

Do‐Youn Oh

Seoul National University Hospital

81H指数

949论文数

4.3W被引数

收录论文 260

发表时间

From screening to surveillance: integrated prevention of Helicobacter pylori–associated gastric cancer in the Asia-Pacific region 从筛查到监测：亚太地区幽门螺杆菌相关胃癌的综合预防

Lancet Regional Health-Western Pacific

IF8.1

2026-08-17

OAAI

Jeesun Yoon; Do-Youn Oh

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial [177Lu]Lu-DOTA-TATE联合长效奥曲肽治疗新诊断的、进展期、2-3级胃肠胰腺神经内分泌肿瘤患者的疗效分析：来自随机III期NETTER-2试验的预先计划和事后分析

EClinicalMedicine

IF10

2026-08-07

OAAI

Diego Ferone; Marianne Pavel; Ken Herrmann; Pamela L. Kunz; Sten Myrehaug; Daniel Halperin; Beth Chasen; Jaume Capdevila; Amparo García-Burillo; Salvatore Tafuto; Secondo Lastoria; Do-Youn Oh; Changhoon Yoo; Stephen Falk; Thorvardur R. Halfdanarson; Maddalena Sansovini; Laura Gerard; Emmanuel Deshayes; Angelina Filice; Ilya Folitar

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02 曲妥珠单抗德鲁替康在HER2表达型胆道或胰腺肿瘤患者中的疗效与安全性：DESTINY-PanTumor02研究的亚组分析

ESMO Open

IF8.3

2026-07-30

OAAI

D.-Y. Oh; I. Ługowska; D. Stroyakovskiy; K.H. Jung; O. Dumas; K. Penkov; A. Dechaphunkul; A. Oaknin; S.T. Kim; N. Starling; B. Chewaskulyong; C. Charonpongsuntorn; D. Doroshow; S.-Y. Hsiao; Y.-P. Hung; L. Jung; N. Kuptsova-Clarkson; F. Michelini; S. Puvvada; F. Meric-Bernstam

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study 度伐利尤单抗联合吉西他滨为基础的化疗方案在晚期胆道癌中的应用：TOURMALINE IIIb期研究的主要结果

Journal of Hepatology

IF33

2026-07-06

OAAI

Do-Youn Oh; Masafumi Ikeda; Teresa Macarulla; Aiwu Ruth He; Joon Oh Park; Masayuki Kitano; Guido Giordano; Kyu-pyo Kim; Thomas Wirth; David Tai; Mohamed Bouattour; Tiziana Pressiani; Farshid Dayyani; Angela Lamarca; Ugochinyere Emeribe; Susanne Radke; Peng Sun; Boris Baur; Arndt Vogel

Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer 开放标签、单臂、II期试验，旨在研究sitravatinib联合tislelizumab方案作为晚期胆道癌二线治疗的疗效。

Journal of Hepatology

IF33

2025-11-24

OAAI

Jeesun Yoon; Choong-kun Lee; Jin Won Kim; Beodeul Kang; Se Jun Park; Ji-Won Kim; Hong Jae Chon; Hye Jin Choi; Myung Ah Lee; Tae-Yong Kim; Do-Youn Oh

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up 替雷利珠单抗 + 化疗在胃癌中的应用：长期RATIONALE-305随机试验随访

Advances in Therapy

IF4

2025-11-18

OAAI

Marcia Cruz-Correa; Do-Youn Oh; Ken Kato; Josep Tabernero; Yuxian Bai; Jianhua Shi; Keun-Wook Lee; Hidekazu Hirano; David Spigel; Lucjan Wyrwicz; Roberto Pazo Cid; Antonio Cubillo Gracián; Yaling Xu; Tao Sheng; Silu Yang; Rui-Hua Xu; Markus Moehler

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial 度万利单抗和齐木利单抗在晚期胃癌、胃食管结合部癌或食管癌中的应用：一项II期临床试验

Nature Medicine

IF50

2025-10-18

OAAI

Yelena Y. Janjigian; Do-Youn Oh; Meredith Pelster; Zev A. Wainberg; Subhransu Prusty; Sandahl Nelson; Amy DuPage; Amy Thompson; Daniel O. Koralek; Edward Allan R. Sison; Sun Young Rha

First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial 一线帕博利珠单抗联合化疗治疗HER2阴性胃或胃食管结合部腺癌：来自随机III期KEYNOTE-859试验的健康相关生活质量

European Journal of Cancer

IF7.1

2025-09-20

PREAI

Maeve A. Lowery; Lucjan S. Wyrwicz; Do-Youn Oh; Kai-Keen Shiu; Patricio Yañez; Yuxian Bai; Min-Hee Ryu; Jeeyun Lee; Fernando Rivera; Gustavo Vasconcelos Alves; Marcelo Garrido; Manuel González Fernández; Jin Li; Timuçin Çil; Felipe Melo Cruz; Shukui Qin; Yanfen Guan; Adriana Valderrama; Sonal Bordia; Sun Young Rha

Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer 度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌的随机III期TOPAZ-1研究中免疫介导的不良事件

ONCOLOGIST

IF4.2

2025-07-01

OAAI

Antonuzzo, Lorenzo; Takahashi, Hidenori; Park, Joon Oh; Sookprasert, Aumkhae; Gillmore, Roopinder; Yang, Sheng-Shun; Cundom, Juan; Petrova, Mila; Vaccaro, Gina; Holmblad, Marielle; Zotkiewicz, Magdalena; Wang, Julie; Rokutanda, Nana; Oh, Do-Youn

YAP as a therapeutic target to reverse trastuzumab resistance YAP作为逆转曲妥珠单抗耐药性的治疗靶点

Gastric Cancer

IF5.1

2025-06-20

OAAI

Ah-Rong Nam; Kyoung-Seok Oh; Ju-Hee Bang; Yoojin Jeong; Sea Young Choo; Hyo Jung Kim; Su In Lee; Jae-Min Kim; Jeesun Yoon; Tae-Yong Kim; Do-Youn Oh

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study Zanidatamab 联合化疗作为HER2阳性晚期胃食管腺癌患者的一线治疗方案：一项多中心、单臂、II期研究的主要结果

lancet oncology

IF0

2025-06-02

PREAI

Elena Elimova; Jaffer Ajani; Howard Burris; Crystal S Denlinger; Syma Iqbal; Yoon-Koo Kang; Jwa Hoon Kim; Keun-Wook Lee; Bruce Lin; Rutika Mehta; Do-Youn Oh; Sun Young Rha; Young Mi Seol; Lin Yang; Mark A Ozog; Phillip M Garfin; Geoffrey Ku

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study 度伐鲁单抗联合化疗在晚期胆道癌中的应用：III期TOPAZ-1研究的3年总生存期更新

Journal of Hepatology

IF33

2025-05-15

OAAI

Do-Youn Oh; Aiwu Ruth He; Shukui Qin; Li-Tzong Chen; Takuji Okusaka; Jin Won Kim; Thatthan Suksombooncharoen; Myung Ah Lee; Masayuki Kitano; Howard A. Burris; Mohamed Bouattour; Suebpong Tanasanvimon; Renata Zaucha; Antonio Avallone; Juan Cundom; Aleksandra Kuzko; Julie Wang; Ioannis Xynos; Arndt Vogel; Juan W. Valle

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 研究总结: 通过招募HER2 IHC状态: DESTINY-PanTumor02的事后分析，曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

ADVANCES IN THERAPY

IF4

2025-03-01

OAAI

Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; Gonzalez-Martin, Antonio; Jung, Kyung Hae; Lugowska, Iwona; Manso, Luis; Manzano, Aranzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305 一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析

ADVANCES IN THERAPY

IF4

2025-03-01

OAAI

Moehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A.; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial 帕博利珠单抗在微卫星高度不稳定和错配修复缺陷型晚期实体瘤中的研究：KEYNOTE-158试验的更新结果

NATURE CANCER

IF28.5

2025-02-20

PREAI

Marabelle, Aurelien; O'Malley, David M.; Hendifar, Andrew E.; Ascierto, Paolo A.; Motola-Kuba, Daniel; Penel, Nicolas; Cassier, Philippe A.; Bariani, Giovanni; De Jesus-Acosta, Ana; Doi, Toshihiko; Longo, Federico; Miller, Wilson H.; Oh, Do-Youn; Gottfried, Maya; Yao, Lili; Jin, Fan; Gozman, Alexander; Maio, Michele

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer (vol 9, 103647, 2024)

ESMO OPEN

IF8.3

2025-01-01

OAAI

Chen, L. -T.; Vogel, A.; Hsu, C.; Chen, M. -H.; Fang, W.; Pangarsa, E. A.; Sharma, A.; Ikeda, M.; Park, J. O.; Tan, C. K.; Regala, E.; Tai, D.; Tanasanvimon, S.; Charoentum, C.; Chee, C. E.; Lui, A.; Sow, J.; Oh, D. -Y.; Ueno, M.; Ramaswamy, A.; Jeo, W. S.; Zhou, J.; Curigliano, G.; Yoshino, T.; Bai, L. -Y.; Pentheroudakis, G.; Chiang, N. -J.; Cervantes, A.; Chen, J. -S.; Ducreux, M.

Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma from the Randomized Phase Ib/II MORPHEUS Trial

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-12-20

OAAI

Ko, Andrew H.; Oh, Do-Youn; Lau, Janet; Mhatre, Shivani K.; Ci, Bo; Machado, Robson; Li, Shi; Bretscher, Michael T.; Reyes-Rivera, Irmarie; Zhu, Jiawen; Zhang, Xiaosong; Patel, Jilpa; Psioda, Matthew A.; Ponz-Sarvise, Mariano

Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer

ESMO OPEN

IF8.3

2024-12-01

PREAI

Kim, T. Y.; Kwak, Y.; Nam, S. K.; Han, D.; Oh, D. Y.; Im, S. A.; Lee, H. S.

Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis

TARGETED ONCOLOGY

IF4

2024-11-10

OAAI

Oh, Do-Youn; Rokutanda, Nana; Zotkiewicz, Magdalena; He, Philip; Stocks, Jennifer; Johnson, Melissa L.

Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer 通俗易懂的总结: 不同类型癌症患者使用futibatinib治疗的安全性分析

FUTURE ONCOLOGY

IF2.6

2024-10-28

OAAI

Meric-Bernstam, Funda; Hollebecque, Antoine; Furuse, Junji; Oh, Do-Youn; Bridgewater, John A.; Anderson, Bailey; Hangai, Nanae; Wacheck, Volker; Goyal, Lipika

研究方向